. 2022 Aug 3;18(10):611–627. doi: 10.1038/s41581-022-00601-z

Table 2.

Senotherapeutic approaches

Senotherapeutic approach	Type	Examples	Refs.
Senolytic interventions	Apoptosis inducers	Quercetin, AP20187, navitoclax, A-1331852, A-1155463, EF24 and venetoclax, antibody-engineered toxic drugs, ginsenoside	^{6,186,217,225,230,231,235}
Senolytic interventions	Immunotherapies	Chimeric antigen receptor T cells, activator of invariant natural killer T cells, vaccines targeting GPNMB (which is overexpressed in senescent cells)	^236–238
Senomorphic drugs	SASP regulators	Metformin, ruxolitinib, rapamycin, resveratrol, melatonin, androgen, oestrogen, oestradiol, glucocorticoids	^{239,243,244,247,250,254–257}
Stem cells and their products	Stem cells	Bone marrow MSCs, pluripotent stem cells, umbilical cord-derived MSCs	^258,259,261
Stem cells and their products	Stem cell-derived extracellular vesicles	MSC-derived extracellular vesicles, dental pulp stem cell-derived extracellular vesicles, antler stem cell-derived extracellular vesicles	^262,264,282
Non-pharmacological therapies	Lifestyle interventions	Habitual moderate exercise, healthy diet, calorie restriction	^{268,269,271,273}
Non-pharmacological therapies	Others	Fractional micro-needling radiofrequency treatment, radio-electric asymmetric conveyer technology	^234,275

MSC, mesenchymal stem cell; SASP, senescence-associated secretory phenotype.